Follow Kamada to never miss an important update.
Kamada delivered its strongest second quarter ever, with revenue rising 23 percent to about $55 million. Profits grew even faster, as net income jumped 26 percent compared to last year. This growth is being driven by the company's shift toward its own proprietary treatments for rare diseases, which earn more profit on every dollar of sales than its older contract manufacturing work.
Management also backed its full-year outlook, expecting to bring in up to $205 million in revenue for 2026. The business is generating healthy cash, bringing in nearly $18 million from its operations during the first half of the year. This financial strength helps protect the company as it continues to build out its own plasma collection centers in the U.S. to secure its supply chain.
Kamada announced that its finance chief, Chaime Orlev, will transition out of the company at the end of 2026 to pursue other opportunities. This gives the board several months to find a replacement and ensures an orderly handoff during a period of record financial performance.
While a change in the top finance role can sometimes create uncertainty, the long notice period suggests this is a planned departure rather than a sudden exit. The company's current momentum and clear full-year guidance should help keep the transition smooth for the next person to step into the role.
Source: GlobeNewsWire
The company will share its latest earnings and a business update on Wednesday, August 12. This will be the first full look at how its new plasma collection centers in the U.S. are contributing to profit margins.
Source: GlobeNewsWire
The firm set a target of $15, which is more than double the current stock price. This reflects a more optimistic view than the average analyst target of $13. It suggests confidence in the company's shift toward owning its own plasma supply and higher-margin specialty treatments.
Source: William Blair
This agreement is a direct result of Kamada's recent expansion into plasma collection. By selling its surplus specialty plasma to other firms, the company is creating a new, high-margin revenue stream that is separate from its own drug manufacturing.
The $50 million total value over three years is meaningful for a company that brought in about $180 million in total revenue last year. It validates the strategy of becoming a vertically integrated supplier rather than just a drug maker.
Source: GlobeNewsWire
Management has a habit of clearing the bars they set, beating profit targets in five of the last eight quarters while maintaining double-digit revenue growth.
| Expectation | |
|---|---|
| EPS | $0.13 |
| Revenue | $53M |